Optimizing Outcomes with Oral Therapies in Plaque Psoriasis

Expert dermatologists examine the evolving role of oral systemic therapies in plaque psoriasis, from PDE4 and TYK2 inhibition to oral IL-23 receptor blockade. The panel reviews head-to-head, long-term, and high-impact site data, safety and monitoring requirements, route-of-administration preferences, and emerging evidence on off-treatment remission and dose de-escalation.